Delcath (DCTH) Q1 2026 Earnings Transcript

Delcath reported Q1 2026 revenue of $25 million, up from $19.8 million a year ago, with gross margin holding at 85% and adjusted EBITDA remaining positive at $3.4 million. Management raised full-year clarity around growth drivers, reaffirming at least $100 million in 2026 revenue, 85%-87% gross margin, and positive adjusted EBITDA for the rest of the year, while also noting $3 million of buybacks in the quarter. The main offset was slower-than-expected site activations, with year-end active center guidance reduced to 37 and target expansion pushed to Q1 2027, though higher patient starts and CHOPIN-driven prescribing trends appear to be supporting demand.

Analysis

The key second-order read-through is that DCTH is shifting from a pure site-activation story to a utilization story. That matters because the revenue curve now has two independently reinforcing levers: more activated centers and higher throughput per center, and the latter is already doing more of the work than the market likely expected. If CHOPIN is genuinely changing prescribing behavior, then the company is not just adding capacity; it is improving conversion of existing capacity, which is much more durable and less binary than site-count expansion.

The most important bear case has moved from execution risk on approvals to execution risk on scaling discipline. Management is openly signaling a slower cadence of center adds, but also implying that capacity constraints inside active centers can still bottleneck growth if backup treatment teams are not trained. That creates a subtle but important asymmetry: the next leg of upside depends more on operational plumbing, referral capture, and physician workflow than on headline clinical readouts, so surprises are more likely to come from monthly utilization data than from trial milestones over the next 6-12 months.

The contrarian takeaway is that the market may be underestimating how much the business can self-fund from here. Positive adjusted EBITDA for the rest of the year plus a sizable cash balance and ongoing buybacks reduce financing overhang, which typically supports multiple expansion in small-cap medtech once investors believe dilution risk is receding. The flip side is that if European reimbursement stays stuck and U.S. utilization normalizes after the CHOPIN pulse, the stock could re-rate back toward a slower-growth commercial device multiple rather than a pipeline-enhanced biotech multiple.

Key Decisions for Investors

• Long DCTH on weakness for a 3-6 month trade: thesis is utilization-driven revenue compounding plus positive EBITDA visibility; risk is a pause in new patient starts or slower-than-expected site conversion.
• Buy DCTH Jan-2027 call spreads to express upside from continued adoption without paying full equity vol; structure around the next 2-3 quarterly updates where utilization trends should matter more than trial commentary.
• Pair trade: long DCTH / short a higher-beta commercial-stage biotech with similar cash burn but no visible self-funding path; this isolates the de-risking from dilution and margin expansion.
• If already long, sell covered calls into strength over the next 1-2 reporting cycles; the stock likely gaps on utilization headlines, but the path is still execution-dependent and prone to mean reversion if site growth stalls.
• Do not chase if the stock rerates sharply on CHOPIN enthusiasm alone; better entry is after the market proves that mid-20% quarter-over-quarter kit growth can persist without adding many more centers.